Regenxbio (RGNX) said Tuesday that the US Food and Drug Administration has accepted and granted priority review to a biologics license application for clemidsogene lanparvovec, or RGX-121, to potentially treat mucopolysaccharidosis II, also known as Hunter syndrome.
The FDA has set a target action date of Nov. 9, the company said.
The drug earlier received orphan drug product, rare pediatric disease, fast track, and regenerative medicine advanced therapy designations from the FDA as well as an advanced therapy medicinal products classification from the European Medicines Agency, Regenxbio said.
Hunter syndrome is a rare genetic disease which can lead to severe developmental delays in children.
Shares of Regenxbio were up more than 6% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。